Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Odyssey Thera has received a milestone payment from Pfizer, following Pfizer's decision to progress a discovery stage drug candidate into preclinical development.
Subscribe to our email newsletter
The drug candidate was studied by Odyssey Thera as part of the ongoing collaboration with Pfizer. The achievement of this milestone is said to be the company’s first such milestone to be earned for contributing to the advancement of a drug candidate.
John Westwick, president and CEO of Odyssey Thera, said: “We are very pleased with the progress of the collaboration with Pfizer. Progress on this and other discovery programs with Pfizer demonstrates the power of our unique cellular analysis platform to improve knowledge of drug mechanisms and selectivity.”